Moxifloxacin Fresenius Kabi (Moxifloxacin Hydrochloride)

Moxifloxacin, the active ingredient in Moxifloxacin Fresenius Kabi, is a fluoroquinolone presented as an intravenous solution for injection use. It treats a range of serious bacterial infections in adult patients, including community‑acquired pneumonia, sinusitis, and intra‑abdominal infections. GNH USA supplies Moxifloxacin Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat infections caused by susceptible bacteria. - Community‑acquired pneumonia: achieves clinical cure by targeting typical and atypical respiratory pathogens. - Acute bacterial sinusitis: reduces symptom duration and bacterial load in sinus mucosa. - Acute bacterial exacerbation of chronic bronchitis: improves airflow and resolves infection. - Skin and skin‑structure infections: eradicates Gram‑positive and Gram‑negative organisms in soft‑tissue infections. - Intra‑abdominal infections: provides coverage for mixed aerobic and anaerobic bacteria in complicated abdominal cases.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Rash: erythematous skin lesions. - Elevated liver enzymes: transient increase in ALT/AST. - Taste disturbance: altered perception of flavors.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles, may occur during or after therapy. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile infection: severe colitis following disruption of gut flora. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome. - Hepatic failure: rare but potentially life‑threatening liver injury.

Moxifloxacin requires careful assessment before use to minimise risks. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic impairment: evaluate liver enzymes regularly during treatment. - QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Concomitant corticosteroids: increase risk of tendon injury; use with caution. - Pregnancy and lactation: prescribe only when benefits outweigh potential fetal or neonatal risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing magnesium or aluminum: reduce absorption; separate administration by at least 2 hours. - Drugs that prolong QT interval (e.g., macrolides, antiarrhythmics): increase risk of cardiac arrhythmias. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase risk of central nervous system stimulation. - Oral contraceptives: possible reduction in contraceptive efficacy; advise additional non‑hormonal methods. - Diabetic agents: heightened risk of hypoglycemia; monitor blood glucose levels.